| Effect of two forms of alendronate administration upon bone mass after two years of treatment. | |
| | |
MedLine Citation:
|
PMID: 11940726 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The efficacy of alendronate in slowing the loss of bone mass, or even in increasing it, in osteoporotic patients and thus reducing the risk of new fractures has been described. Nevertheless, the way of taking this drug, together with its side effects, sometimes produces withdrawals. In this study, we analyzed if an alternative way of taking the alendronate improves the follow-up of the treatment and if it had the same effect on bone mineral metabolism than the traditional way of prescription. An open, intention-to-treat study, with follow-up of 2 yr was conducted. Eighty women suffering from postmenopausal osteoporosis were included in the study. They were classified in a random manner into two groups, each one of them received 10 mg/d alendronate, together with 1.2 g of calcium and 800 IU of Vitamin D3. Group I received the drug fasting, before breakfast, as usually prescribed and group II received the alendronate fasting, at noon, before lunch. Biochemical markers of bone remodeling were determined. Total alkaline phosphatase, osteocalcin, tartrate-resistant acid phosphatase, urine calcium/creatinine ratio, crosslinked N-telopeptides of type I collagen/creatinine ratio, serum calcium, and parathyroid hormone were also determined, and a lateral dorsolumbar radiography of the spine was performed. Bone mineral density was determined in the lumbar spine by dual-energy X-ray absorptiometry and quantitative computed tomography and by dual-energy X-ray absorptiometry in the proximal femur. Both groups showed an increase in bone mineral density in the lumbar spine and in the proximal femur, which was statistically significant after 1 yr of treatment in the range between 1.5% and 4.3%, depending on the anatomical localization where bone mineral density was measured. There was also an important decrease in the biochemical markers of bone remodeling, between 5.6% and 42.5%, depending on the biochemical marker; the decrease of amino-terminal telopetide during the first year was more important. The group that received alendronate in the morning reported a significantly higher number of withdrawals than the group that received the drug at noon. The alternative administration of 10 mg alendronate at noon had the same effect on bone mineral metabolism than its traditional administration in the morning, but the rate of withdrawals was significantly lower. |
| | |
Authors:
|
M Sosa; D Hernández; M C Segarra; A Gómez; E de la Peña; P Betancor |
Related Documents
:
|
9502306 - Bone turnover in amenorrhoeic and eumenorrhoeic women distance runners. 10619976 - Effect of recombinant human growth hormone in elderly osteoporotic women. 8118746 - Effects of salmon calcitonin suppositories on bone mass and turnover in established ost... 18167616 - Influence of synovial fluid on human osteoblasts: an in vitro study. 21060216 - [basic study for the measurement of the bone mineral density of the calcaneus by using ... 7573376 - Limb skeleton and locomotor adaptations of apidium phiomense, an oligocene anthropoid f... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry Volume: 5 ISSN: 1094-6950 ISO Abbreviation: J Clin Densitom Publication Date: 2002 |
Date Detail:
|
Created Date: 2002-04-09 Completed Date: 2002-08-20 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9808212 Medline TA: J Clin Densitom Country: United States |
Other Details:
|
Languages: eng Pagination: 27-34 Citation Subset: IM |
Affiliation:
|
Department of Medical and Surgical Sciences, University of Las Palmas de Gran Canaria, Hospital University Insular, Service of Internal Medicine, Bone Metabolic Unit, Las Palmas de Gran Canaria, Canary Islands, Spain. msosa@cicei.ulpgc.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Absorptiometry, Photon Aged Alendronate / administration & dosage*, therapeutic use Bone Density / drug effects* Bone Remodeling / drug effects* Female Humans Middle Aged Osteoporosis, Postmenopausal / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
66376-36-1/Alendronate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lumbar spine bone measurements in infants: whole-body vs lumbar spine dual X-ray absorptiometry scan...
Next Document: Reproducibility of DXA in obese women.